 |
인쇄하기
취소
|
Handok buys 20% share of Genexine
Handok Pharmaceutical Co. Wednesday purchased 19.72 percent in shares of Genexine, a Korean biopharmaceutical company.
“Handok and Genexine already signed a memorandum of understanding in February to jointly develop new sustained release human growth hormone (GX-H9),” said Kim Young-jin, Chairan of Hankdok Pharmaceutical.
Genexine is a biotech company specialized in new generation therape...
“Handok and Genexine already signed a memorandum of understanding in February to jointly develop new sustained release human growth hormone (GX-H9),” said Kim Young-jin, Chairan of Hankdok Pharmaceutical.
Genexine is a biotech company specialized in new generation therape...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.